In fact, different mechanisms of primary and secondary resistances occurring in KRAS-mutated NSCLC patients treated with these inhibitors can explain these clinical results (Figure 2) [141,143,144,145,146,147,148,149,150,151,152,153,154,155]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.